Simpson G M, Pi E H, Sramek J J
Hosp Community Psychiatry. 1986 Apr;37(4):362-9. doi: 10.1176/ps.37.4.362.
The authors review recent research on definition, diagnosis, neuropathophysiology, treatment, management, and factors that increase risk of tardive dyskinesia, a severe and often unremitting movement disorder associated with neuroleptic treatment. Supersensitivity of dopamine receptors is believed to be the cause of tardive dyskinesia, and treatment strategies have consisted of pharmacologic blockade of dopamine receptors, depletion of dopamine, and restoration of the balance between the dopaminergic system and the neurotransmitter systems that regulate it. Several experimental neuroleptics that do not appear to cause tardive dyskinesia may be approved for use in the United States, but for now preventive measures, such as wise prescription and gradual tapering of neuroleptics, as well as careful monitoring for symptoms of tardive dyskinesia are the clinician's best defense.
作者回顾了近期关于迟发性运动障碍的定义、诊断、神经病理生理学、治疗、管理以及增加其风险的因素的研究。迟发性运动障碍是一种与抗精神病药物治疗相关的严重且通常持续存在的运动障碍。多巴胺受体超敏反应被认为是迟发性运动障碍的病因,治疗策略包括对多巴胺受体的药物性阻断、多巴胺耗竭以及恢复多巴胺能系统与其调节性神经递质系统之间的平衡。几种似乎不会导致迟发性运动障碍的实验性抗精神病药物可能会在美国获批使用,但目前,预防措施,如明智地开具抗精神病药物处方并逐渐减药,以及仔细监测迟发性运动障碍的症状,是临床医生的最佳防御手段。